Is Dactinomycinum [INN-Latin] Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Dactinomycinum [INN-Latin]? Is Dactinomycinum [INN-Latin] safe for nursing mother and child? Does Dactinomycinum [INN-Latin] extracts into breast milk? Does Dactinomycinum [INN-Latin] has any long term or short term side effects on infants? Can Dactinomycinum [INN-Latin] influence milk supply or can Dactinomycinum [INN-Latin] decrease milk supply in lactating mothers?
Dactinomycinum [INN-Latin] lactation summary
![Dactinomycinum [INN-Latin] is dangerous in breastfeeding](/images/breastfeeding/dangerous-in-breastfeeding.jpg "Dactinomycinum [INN-Latin] breastfeeding")
- DrLact safety Score for Dactinomycinum [INN-Latin] is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Dactinomycinum [INN-Latin] may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Dactinomycinum [INN-Latin] may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Dactinomycinum [INN-Latin] .
- Usage of Dactinomycinum [INN-Latin] is in contradiction to breastfeeding hence if it is must to use Dactinomycinum [INN-Latin] and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Dactinomycinum [INN-Latin] usage in lactation
Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 10 days of pumping-and-dumping.
Answer by DrLact: About Dactinomycinum [INN-Latin] usage in lactation
No information is available on the use of Dactinomycinum [INN-Latin] during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during Dactinomycinum [INN-Latin] therapy and for 14 days after the last dose.
Alternate Drugs
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Dactinomycin(Dangerous)
Tamoxifen(Dangerous)
Ipilimumab(Unsafe)
Mitoxantrone(Dangerous)
Cetuximab(Unsafe)
Carboplatin(Dangerous)
Mercaptopurine(Safe)
Gemcitabine(Dangerous)
Paclitaxel(Dangerous)
Fluorouracil(Dangerous)
Nivolumab(Unsafe)
Hydroxyurea(Low Risk)
Alemtuzumab(Low Risk)
Vinblastine(Dangerous)
Etoposide(Dangerous)
Docetaxel(Dangerous)
Rituximab(Low Risk)
Pazopanib(Unsafe)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Bevacizumab(Low Risk)
Vinorelbine(Dangerous)
Cyclophosphamide(Dangerous)
Dacarbazine(Dangerous)
Cisplatin(Unsafe)
Trastuzumab(Unsafe)
Busulfan(Dangerous)
Letrozole(Dangerous)
Imatinib(Unsafe)
Erlotinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Exemestane(Dangerous)
Azelaic Acid(Safe)
Dasatinib(Unsafe)
Dactinomycin(Dangerous)
Nilotinib(Unsafe)
Vincristine(Dangerous)
Dactinomycin(Dangerous)
Fusidic Acid(Safe)
Dactinomycin(Dangerous)